Chimeric antigen receptors that target CD33

Abstract

Chimeric antigen receptors (CARs) are described that contain binding domains derived from a novel set of CD33-binding antibodies. The CARs contain optimized short and intermediate spacer regions. The disclosure also provides methods of cell expansion / activation that utilize IL-2, IL-7, IL-15, and / or IL-21 to improve cell proliferation and cytolysis of the described CARs.

Description

[Technical Field]

[0001] This application claims priority to U.S. Provisional Patent Application No. 63 / 003,213, filed on 31 March 2020, which is incorporated herein by reference in its entirety as if it were fully contained herein.

[0002] Statement on federally supported research or development This invention was made with government support under CA234203 and CA245594 granted by the National Institutes of Health. The government has certain rights to this invention.

[0003] Sequence listing reference The sequence listing relating to this application is provided in text format instead of being a paper copy and is incorporated herein by reference. The name of the text file containing the sequence listing is 2GU3967_ST25.txt. The text file is 267KB in size, was created on March 31, 2021, and filed electronically via EFS-Web.

[0004] Areas of this disclosure This disclosure provides a chimeric antigen receptor (CAR) having a binding domain derived from a novel set of CD33-binding antibodies, including optimized short and intermediate spacer regions. This disclosure also provides a method for cell growth / activation processes utilizing IL-2, IL-7, IL-15, and / or IL-21 to improve cell proliferation and cytolysis of the described CARs. [Background technology]

[0005] According to the World Health Organization, cancer is the second leading cause of death globally, accounting for an estimated 9.6 million deaths in 2018. Acute myeloid leukemia (AML) is a type of cancer caused by malignant tumors of clonal proliferative myeloblastic cells. In the United States, there are 20,000 new cases of AML annually, and 11,000 people die from AML each year (Siegel et al., 2021, CA Cancer J Clin. 71(1): pp. 7-33). While young patients with AML can achieve high complete remission rates of 60% to 80% with conventional chemotherapy (Dohner et al., 2017, Blood. 129(4): pp. 424-447), treatment outcomes for elderly patients aged 65 and over remain inadequate, with as many as 70% dying from the disease within one year of diagnosis (Meyers et al., Appl Health Economic Health Policy, 11: pp. 275-286, 2013). Unfortunately, due to the chemotherapy resistance of leukemia stem cells, relapse after conventional treatment is common (Eppert et al., 2011. Nat. Med. 17(9): pp. 1086-1093), and current treatment options for relapsed / refractory (R / R) AML are poor, resulting in a 12-month overall survival rate of less than 30%.

[0006] For many years, the preferred treatments for cancer were surgery, chemotherapy, and / or radiation therapy. In recent years, more targeted therapies have emerged that specifically target cancer cells by identifying and utilizing specific molecular and / or immunophenotypic changes observed primarily in cancer cells. For example, many cancer cells preferentially express certain markers on their cell surface, and these markers have provided targets for antibody-based therapies.

[0007] CD33 is a member of the sialic acid-binding immunoglobulin-like lectin (SIGLEC) protein family. It is a 67 kDa glycosylated transmembrane protein. CD33 (also known as SIGLEC-3) is a myeloid differentiation antigen found in at least some leukemia cells, and possibly in some cases in AML stem cells, in almost all patients with AML. Based on this widespread expression pattern, CD33 has been widely pursued as a therapeutic target in AML. Recent data from several randomized studies have demonstrated that gemtuzumab ozogamicin (GO), a CD33 antibody-drug conjugate, improves survival when added to chemotherapy in a defined subset of patients with newly diagnosed AML. This data confirms that CD33 is the first (and so far only) target for immunotherapy in AML. In parallel with the development of new and more effective CD33-targeted therapies (e.g., antibody-drug conjugates, radioactive immunoconjugates, bispecific antibodies, chimeric antigen receptor [CAR]-modified T cells) to overcome the limitations pointed out by GO, there is growing interest in CD33 as a drug target for other malignant and non-malignant disorders. These efforts include targeting CD33 splice variants not recognized by GO, as well as targeting CD33+ tumor cells in other hematological malignancies, CD33+ myeloid-derived suppressor cells (MDSCs) in various diseases, and normal CD33+ microglia in Alzheimer's disease (Walter, Expert Opin Biol Ther. 2020, 20(9):955-958).

[0008] Full-length CD33 protein (CD33 FL CD33 is characterized by a V-set immunoglobulin (Ig)-like domain at the distal membrane of the amino terminus and a C2-set Ig-like domain at the proximal membrane in its extracellular portion (Figure 2). Shorter isoforms of CD33 exist. These shorter isoforms of CD33 have a V-set domain (CD33 ΔE2It includes one variant lacking exon 2, which codes for ). At least at the mRNA level, CD33 ΔE2 CD33 is widely expressed in bone marrow and peripheral blood myeloid cells of patients with AML. However, almost all commercially and clinically available CD33 antibodies currently recognize the immunodominant V-set Ig-like domain. This means that these antibodies do not recognize CD33 ΔE2 This means that shorter forms of CD33, such as those lacking the V-set domain, are not recognized. ΔE2 Preferential transcription and CD33 FL This can explain an observation made in a clinical trial of pediatric AML in patients with a single nucleotide polymorphism in the CD33 gene that results in reduced translation, in which patients did not benefit from the addition of gemtuzumab ozogamicin (which also binds to the V set domain of CD33) to intensive chemotherapy.

[0009] Beyond antibody-based therapies, significant progress has been made in genetically engineering T cells of the immune system to target and kill unwanted cells, such as cancer cells. Many of these T cells are genetically engineered to express chimeric antigen receptors (CARs). A CAR is a protein containing several distinct microcomponents that enable genetically modified T cells to recognize and kill cancer cells. The microcomponents include at least an extracellular component and an intracellular component. The extracellular component includes a binding domain that specifically binds to markers (e.g., CD33) that preferentially exist on the surface of unwanted cells. When the binding domain binds to such a marker, the intracellular component signals the T cell to destroy the bound cell. The CAR further includes a transmembrane domain that can link the extracellular component to the intracellular component.

[0010] Other small components that can enhance the function of CARs are also available. For example, spacer regions can provide additional structural flexibility to CARs, often increasing the ability of binding domains to target cell markers. The appropriate length of the spacer region within a particular CAR may depend on numerous factors, including how proximal or distal the target marker is located from the surface of the undesirable cell membrane.

[0011] When performed ex vivo, genetically modifying T cells can involve numerous cell manipulation steps, and it has been observed that different manipulation conditions can affect the cancer cell-killing properties of the cells. Therefore, when designing CARs and genetically modifying cells to express those CARs, numerous considerations must be taken into account, including target cell markers, the presence and / or length of spacers, and ex vivo manipulation procedures. [Prior art documents] [Non-patent literature]

[0012] [Non-Patent Document 1] Siegel et al., 2021, CA Cancer J Clin.71(1):7-33 [Non-Patent Document 2] Dohner et al., 2017. Blood. 129(4): 424-447. [Non-Patent Document 3] Meyers et al., Appl Health Economic Health Policy, 11: pp. 275-286, 2013. [Non-Patent Document 4] Eppert et al., 2011. Nat. Med. 17(9): 1086-1093. [Non-Patent Document 5] Walter, Expert Opin Biol Ther. 2020, 20(9):955-958. [Overview of the project] [Means for solving the problem]

[0013] The present disclosure provides chimeric antigen receptors (CARs) for the treatment of CD33-related disorders. The CARs include binding domains derived from a novel set of anti-CD33 antibodies. In certain embodiments, the CARs include binding domains that bind CD33 regardless of which CD33 variant the patient expresses (CD33 FL or CD33 ΔE2 ). These CD33 binding domains are referred to as "pan" binders. In certain embodiments, the pan binder binds to the membrane-proximal C2-set Ig-like domain of CD33 (see Figure 2). In certain embodiments, these pan binders are derived from the antibodies: 9G2, 6H9, 3A5 variant 1 (3A5v1), 3A5 variant 2 (3A5v2), 7D5 variant 1 (7D5v1), 7D5 variant 2 (7D5v2), 1H7, and 2D5, and can include single-chain variable fragments (scFvs) of these antibody binding domains. Additional CD33 targeting antibodies disclosed herein that bind to the V-set domain of CD33 include 5D12 and 8F5. These antibodies provide additional CAR-based treatment options for patients expressing CD33 FL . CD33 targeting antibodies disclosed herein that bind to the C2-set domain of CD33, but only when the V-set domain is absent, include 12B12, 11D11, 7E7, 11D5, and 13E11.

[0014] Combinations of antibody-based binding domains can be selected for use in CARs based on whether the subject expresses or lacks the V-set domain of CD33. For example, when the subject expresses the V-set domain, combination therapies including one or more of the binding domains of 6H9, 9G2, 3A5, 7D5, 1H7, and 2D5 can be considered to be selected in combination with one or more of 5D12 and 8F5. When the subject does not express the V-set domain, combination therapies including one or more of the binding domains of 6H9, 9G2, 3A5, 7D5, 1H7, and 2D5 can be considered to be selected in combination with one or more of 12B12, 11D5, 13E11, 11D11, and 7E7.

[0015] In certain embodiments, the disclosure provides a CAR having a short or intermediate spacer region. In certain embodiments, the short spacer region comprises the hinge region of IgG4 (12 amino acids). In certain embodiments, the intermediate spacer region comprises the hinge region of IgG4 and the CH3 domain (totaling 131 amino acids).

[0016] In certain embodiments, the disclosure provides a method for increasing and activating genetically modified T cells expressing the CARs disclosed herein by utilizing a combination of cytokines IL-7, IL-15, and IL-21. In certain embodiments, the disclosure provides a method for increasing and activating genetically modified T cells expressing the CARs disclosed herein by utilizing a combination of cytokines including IL-2.

[0017] The CARs disclosed herein can be used to treat acute myeloid leukemia (AML) and other CD33+ disorders. [Brief explanation of the drawing]

[0018] [Figure 1] CD33 is overexpressed in AML compared to hematopoietic stem cells, as shown in the CD33 expression data for acute myeloid leukemia (AML) and normal hematopoietic cells. Relative expression data were collected from bloodspot.eu. HSPC, hematopoietic stem / progenitor cells; MPP, pluripotent progenitor cells. **** p<0.0001, ns Not significant by multiple t-tests using Benjamini, Krieger and Yekutieli's two-step linear step-up procedure, Q=1%. [Figure 2] Illustrations of full-length CD33 (CD33FL) and CD33 with exon 2 deleted, resulting in the deletion of the V set domain (CD33ΔE2). Antibodies that bind to CD33FL only (anti-CD33FL), CD33ΔE2 only (anti-CD33ΔE2), or CD33FL and CD33ΔE2 (anti-CD33FL+ΔE2 or anti-CD33PAN) are shown. [Figure 3] This is a schematic diagram of an artificial CD33 molecule (CD33ΔE3-4) with deletions of exons 3 and 4 resulting in membrane-proximal rearrangement of the CD33FL and V set domains, or an insertion of either two C2 set domains of CD22 ("CD33FL+CD22 2D") or four C2 set domains of CD22 ("CD33FL+CD22 4D"). CD33ΔE3-4 was engineered using site-directed mutagenesis to splice out CD33 amino acids (aa) 140-232 of the human CD33FL extracellular domain (ECD). CD33FL+CD22 4D was generated using endogenous CD33 signal peptides (aa1-17), a 6-histidine tag, a 3× glycine linker, human CD33 ECD (aa18-259), a portion of human CD22 ECD containing C2 type domains 3-6 (aa331-683), the CD33 transmembrane domain, and the CD33 intracellular domain (aa260-364). CD22 aa331-504 (C2 type domains 3 and 4) were removed from CD33FL+CD22 24 to generate CD33FL+CD22 2D. [Figure 4]This figure shows a cloning strategy for constructing CD33 CAR expression constructs. (i) Supernatants from antibody-secreting mouse hybridoma cells were screened for pan-CD33 binding activity, then for lack of binding to CD33 null cell lines, and the best individual hybridomas were selected. Antibody isotyping was performed, RNA was extracted, and used for rapid amplification (RACE) amplification (Takara) of cDNA ends and subsequent isotype-specific polymerase chain reaction (PCR) based amplification. (ii) Cloning of antibody variable region sequences was performed using pRACE (Takara) or TOPO (Invitrogen) standard cloning vectors. (iii) Plasmid DNA was purified from individual bacterial colonies and Sanger DNA sequencing was performed to obtain at least three individual identical cDNA sequences corresponding to the respective antibody variable regions for both the antibody heavy chain and light chain. (iv) The antibody variable region cDNA sequences were translated into amino acid sequences using the ExPASy.org translation tool. (v) The amino acid sequences for each individual antibody variable region were submitted to the Integrated DNA Technologies (IDT, Coralville, IA) website for human codon optimization. (vi) Next, the codon-optimized single-stranded variable region (scFv) nucleic acid sequence was combined with the nucleic acid sequence contained within the CAR-backed lentiviral backbone-41BB-3z-T-CD19t, in particular the sequence within the EF1 promoter adjacent to the 5' end of the GM-CSFR signal peptide containing the granulocyte-macrophage colony-stimulating factor receptor (GM-CSFR) signal peptide, which was added to the 5' side of the antibody's HC variable region, followed by a mobile Gly-Ser linker sequence, then the antibody LC variable region, and then the linker sequence derived from the CAR-backed lentiviral backbone-41BB-3z-T-CD19t. (vii) Next, the complete nucleotide sequence was submitted to IDT for the synthesis of gBlock. (viii) gBlock was cloned during TOPO, and its nucleic acid sequence was verified by Sanger DNA sequencing.(ix) All gBlocks were constructed to include a universal priming sequence, CAR_universal_forward primer, and CAR_universal_reverse primer. (x) PCR amplification was then performed using a suitable TOPO vector as a template, proofreading DNA polymerase, and the CAR_universal_forward primer and a reverse primer selected from three options: CAR_universal_rev_sh, CAR_universal_rev_int, or CAR_universal_rev_long. In these primers, rev indicates reverse, sh indicates a short linker, int indicates an intermediate-length linker, and long indicates a long linker within the CAR construct. (xi) The recipient plasmid (lentiviral backbone-41BB-3z-T-CD19t with sh, int, or long linker) was digested with RsrII / NheI, and the cleaved plasmid and PCR product were gel-purified. (xii) Gibson assembly (NEB) was performed using RsrII / NheI digested recipient plasmids (lentiviral skeleton-41BB-3z-T-CD19t with sh, int, or long linkers) and appropriate PCR amplicons. (xiii) Sanger DNA sequencing validation was used to confirm the scFv and linkers contained in each plasmid. (vii) Maxiprep and lentiviral packaging followed. [Figure 5A]This figure shows that the antitumor effect of CD33 / CD3 BsAb against human myeloid leukemia cells is enhanced by a reduction in the binding distance from the cell membrane. Human CD33+ myeloid leukemia cell lines ((5A)ML-1, (5B)HL-60, (5C)K562) with CRISPR / Cas9-mediated deletion of the endogenous CD33 locus were engineered to overexpress either CD33FL or CD33ΔE3-4 via lentiviral gene transfer. Relative expression of the target protein was assessed by flow cytometry with the V-set domain CD33 antibody, P67.6, and representative histograms are shown in the lower right panel. Cells were then treated with V-set domain targeting CD33 / CD3 BsAb at a concentration of 1000 pg / mL and healthy donor T cells enriched from unstimulated peripheral blood mononuclear cells collected from healthy adult volunteers with the shown effector:target (E:T) cell ratio (upper panel). Bone marrow cells were also treated with gemtuzumab ozogamicin (GO) at the indicated concentrations (lower left panel). Cytotoxicity was quantified by flow cytometry as the change in the percentage of dead cells measured by 4',6-diamidino-2-phenylindole (DAPI) staining at 2 days (for BsAb) or 3 days (for GO). [Figure 5B]This figure shows that the antitumor effect of CD33 / CD3 bispecific antibodies (BsAbs) against human myeloid leukemia cells is enhanced by a decrease in the binding distance from the cell membrane. Human CD33+ myeloid leukemia cell lines with CRISPR / Cas9-mediated deletion of the endogenous CD33 locus ((5A)ML-1, (5B)HL-60, (5C)K562) were engineered to overexpress either CD33FL or CD33ΔE3-4 via lentiviral gene transfer. The relative expression of the target protein was evaluated by flow cytometry using the V-set domain CD33 antibody, P67.6, and representative histograms are shown in the lower right panel. The cells were then treated with a V-set domain-targeting CD33 / CD3 BsAb at a concentration of 1000 pg / mL and healthy donor T cells enriched from unstimulated peripheral blood mononuclear cells collected from healthy adult volunteers with the indicated effector:target (E:T) cell ratio (upper panel). Bone marrow cells were also treated with gemtuzumab ozogamicin (GO) at the indicated concentration (lower left panel). Cytotoxicity was quantified by flow cytometry as the change in the percentage of dead cells measured by 4',6-diamidino-2-phenylindole (DAPI) staining at 2 days (for BsAb) or 3 days (for GO). [Figure 5C]This figure shows that the antitumor effect of CD33 / CD3 bispecific antibodies (BsAbs) against human myeloid leukemia cells is enhanced by a decrease in the binding distance from the cell membrane. Human CD33+ myeloid leukemia cell lines with CRISPR / Cas9-mediated deletion of the endogenous CD33 locus ((5A)ML-1, (5B)HL-60, (5C)K562) were engineered to overexpress either CD33FL or CD33ΔE3-4 via lentiviral gene transfer. The relative expression of the target protein was evaluated by flow cytometry using the V-set domain CD33 antibody, P67.6, and representative histograms are shown in the lower right panel. Cells were then treated with a V-set domain targeting CD33 / CD3 BsAb at a concentration of 1000 pg / mL and healthy donor T cells enriched from unstimulated peripheral blood mononuclear cells collected from healthy adult volunteers with the indicated effector:target (E:T) cell ratio (upper panel). Bone marrow cells were also treated with gemtuzumab ozogamicin (GO) at the indicated concentration (lower left panel). Cytotoxicity was quantified by flow cytometry as the change in the percentage of dead cells measured by 4',6-diamidino-2-phenylindole (DAPI) staining at 2 days (for BsAb) or 3 days (for GO). The anti-V-set domain targeting CD33 / CD3 BsAb was constructed in scFv-scFv format using constructs referred to herein as RC1 or A3, utilizing the sequence shown in Sequence ID No. 377 and described in U.S. Patent Application Publication No. 2016 / 0317657. *p<0.05;**p<0.01;***p<0.001. [Figure 6]This figure shows that the antitumor effect of CD33 / CD3 BsAb on human acute lymphoblastic leukemia cells engineered to express the CD33 protein is enhanced by a reduction in the binding distance from the cell membrane. Human CD33neg acute lymphoblastic leukemia (ALL) cell line RS4;11 was engineered to overexpress either CD33FL or CD33ΔE3-4 via lentiviral gene transfer. Relative expression of the target protein was assessed by flow cytometry using the V-set domain CD33 antibody, P67.6, and representative histograms are shown in the lower panel. Cells were then treated with a concentration of 1000 pg / mL of V-set domain targeting CD33 / CD3 BsAb and healthy donor T cells enriched from unstimulated peripheral blood mononuclear cells collected from healthy adult volunteers with the indicated effector:target (E:T) cell ratio (upper panel). Cytotoxicity was quantified by flow cytometry after 2 days as the change in the percentage of dead cells measured by 4',6-diamidino-2-phenylindole (DAPI) staining. The anti-V set domain-directed CD33 / CD3 BsAb was constructed in scFv-scFv format using constructs referred to herein as RC1 or A3, utilizing the sequence shown in Sequence ID No. 377 and described in U.S. Patent Application Publication No. 2016 / 0317657. *p<0.05; **p<0.01; ***p<0.001. [Figure 7]This figure shows that the antitumor effect of CD33 / CD3 BsAb decreases with increasing binding distance from the cell membrane. Human myeloid leukemia cell lines with CRISPR / Cas9-mediated deletion of the endogenous CD33 locus (ML-1 [upper panel], K562 [lower panel]) were engineered to overexpress CD33FL, CD33FL+CD22 2D, or CD33FL+CD22 4D via lentiviral gene transfer. Relative expression of CD33 constructs was assessed by flow cytometry using the V-set domain CD33 antibody, P67.6 (right panel). Cells were then treated with V-set domain targeting CD33 / CD33 BsAb at the indicated concentrations (pg / mL) and healthy donor T cells enriched from healthy donor unstimulated peripheral blood mononuclear cells with a 1:1 E:T cell ratio. Cytotoxicity was quantified by flow cytometry after 2 days as the change in the percentage of dead cells measured by 4',6-diamidino-2-phenylindole (DAPI) staining. The anti-V set domain-directed CD33 / CD3 BsAb was constructed in scFv-scFv format using constructs referred to herein as RC1 or A3, utilizing the sequence shown in Sequence ID No. 377 and described in U.S. Patent Application Publication No. 2016 / 0317657. *p<0.05; **p<0.01; ***p<0.001. [Figure 8A] This figure shows the results of flow cytometry testing of mouse CD33PAN antibodies (clones 1H7, 9G2, 6H9, 3A5, 7D5, 2D5) against CD33+ parental ML-1 cells, ML-1 cells with CRISPR / Cas9-mediated deletion of CD33 ("CD33 KO"), ML-1 cells with CRISPR / Cas9-mediated knockout of the CD33 locus and expression of non-human primate CD33 ("NHP CD33"), and CD33negREH sublines engineered to express CD33FL or CD33ΔE2, as shown. Negative controls using only secondary antibodies are shown. [Figure 8B]This figure shows the results of flow cytometry testing of mouse CD33V set antibodies (clones 8F5, 5D12) against CD33+ parental ML-1 cells, ML-1 cells with CRISPR / Cas9-mediated deletion of CD33 ("CD33 KO"), ML-1 cells "NHP CD33" with CRISPR / Cas9-mediated knockout of the CD33 locus and expression of non-human primate CD33, and CD33negREH sublines engineered to express CD33FL or CD33ΔE2, as shown. Negative controls with only secondary antibodies are shown. [Figure 8C] This figure shows the results of flow cytometry testing of mouse CD33C2 set-specific antibodies (clones 11D5, 13E11, 11D11, 7E7) against CD33+ parental ML-1 cells, ML-1 cells with CRISPR / Cas9-mediated deletion of CD33 ("CD33 KO"), ML-1 cells with CRISPR / Cas9-mediated knockout of the CD33 locus and expression of non-human primate CD33 ("NHP CD33"), and CD33negREH sublines engineered to express CD33FL or CD33ΔE2, as shown. Negative controls using only secondary antibodies are shown. [Figure 9]This figure shows that reducing the binding distance from the cell membrane enhances the antitumor efficiency of CD33 chimeric antigen receptor (CAR) T cells. Human myeloid leukemia cell line K562, with a CRISPR / Cas9-mediated deletion of the endogenous CD33 locus, was engineered to overexpress CD33FL or CD33ΔE3-4 via lentiviral gene transfer. Relative expression of the target protein was assessed by flow cytometry via the V-set domain CD33 antibody, P67.6, with representative histograms shown in the lower panel. The efficacy of V-set domain-directed CAR T cells was evaluated by chromium 51 release. In CAR T cell generation, healthy donor-negative selected human CD8+ T cells were transduced with epHIV7 lentivirus encoding scFv derived from CD33V set / CD3 BsAb, as described in Figures 3, 5, and 6, linked to an IgG4 CH3 domain spacer, CD28 transmembrane domain, CD3 zeta and 4-1BB intracellular signaling domain, and a cleaved CD19 (tCD19) transduction marker. tCD19 CD8+ CAR-T cells were sorted and grown in IL-7 and IL-15 (10 ng / mL; Peprotech, Rocky Hill, NJ, USA) for 14 days each, with alternating medium and cytokine changes. CAR-T cell toxicity was assessed following a 4-hour incubation with chromium 51-labeled targets. [Figure 10] This figure shows the different surface expression levels of CD33 in AML cell lines. CD33 expression, as measured by Quantibrite-PE, was determined by staining human AML cell lines with PE conjugate p67.6 antibody. [Figure 11A] The C2 set-directed scFv(1H7) was cloned into a chimeric antigen receptor (CAR) construct with a short spacer. The figure contains a map of the cloned sequence. [Figure 11B] The C2 set-directed scFv(1H7) was cloned into a chimeric antigen receptor (CAR) construct with an intermediate spacer. The figure contains a map of the cloned sequence. [Figure 11C]The C2 set-directed scFv(1H7) was cloned into a chimeric antigen receptor (CAR) construct with a long spacer. The figure contains a map of the cloned sequence. [Figure 12] This figure shows 1H7 CAR-T cells growing in vitro in response to cytokines. Healthy donor-negative selected human CD8+ T cells were transduced with epHIV7 lentivirus encoding CD33V set-conjugated scFv 1H7, linked to an intermediate-length IgG4 CH3 domain spacer, CD28 transmembrane domain, CD3 zeta and 4-1BB intracellular signaling domain, and a truncated CD19 (tCD19) transduction marker (as shown in Figure 11). tCD19 CD8+ CAR-T cells were sorted and grown in IL-7 and IL-15 (10 ng / mL; Peprotech, Rocky Hill, NJ, USA) for 12 days each, with alternating medium and cytokines. Growth, cell diameter, and cell death were assessed every other day using a cellometer with propidium iodide and acridine orange, as per the manufacturer's instructions (Nexcelcom, Lawrence, Massachusetts). [Figure 13] This figure shows the percentage of naive T cells slightly enhanced following cytokine increase in 1H7 CAR-T cells with a long spacer. Following IL-7 and IL-15 cytokine increase, as shown in Figure 12, cells were stained with antibodies fluorescently conjugated to CD45RA and CCR7, and the percentages of naive (CCR7+CD45RA+), central memory (CCR7+CD45RA-), effector memory (CCR7-CD45RA-), or effector memory RA (CCR7-CD45RA+) cells were evaluated. Expression was then measured after 4 days by multi-parameter flow cytometry (MFC). The experiment was repeated with additional healthy donors to confirm the results. [Figure 14A]This figure shows 1H7 CAR-T cells with short, intermediate, and long spacers exhibiting equivalent expression of activation and proliferation markers following cytokine increases. As shown in Figure 12, following IL-7 and IL-15 cytokine increases, cells were stained with antibodies fluorescently conjugated to surface and intracellular markers for activation (CD69) and proliferation (Ki-67). Expression was then measured by MFC after 4 days. The experiment was repeated with additional healthy donors to confirm the results. [Figure 14B] This figure shows 1H7 CAR-T cells with short, intermediate, and long spacers exhibiting equivalent expression of immune checkpoint markers following cytokine increases. Following IL-7 and IL-15 cytokine increases, as shown in Figure 12, cells were stained with antibodies fluorescently conjugated to immune checkpoint markers (PD-1, TIM3, LAG-3, TIGIT, KLRG1, 2B4). Expression was then measured by MFC after 4 days. The experiment was repeated with additional healthy donors to confirm the results. [Figure 15-1] This figure shows 1H7 CAR-T cells with intermediate and short spacers exhibiting antigen-specific enhanced cytotoxicity against multiple AML cell lines. Following IL-7 and IL-15 cytokine enhancement as shown in Figure 12, target cells were labeled with chromium 51 (Cr51) for 2 hours and then exposed to 1H7 CAR-T cells with short, intermediate (int), or long spacers for 4 hours. The supernatant was then collected and analyzed for Cr51 using a scintillation counter (TopCount, Perkin Elmer, Waltham, MA). Percent cytotoxicity was calculated as (sample lysis - background) / (maximum lysis - background lysis) × 100, where background lysis is the spontaneous release of Cr51 over 4 hours and maximum lysis is the release of Cr51 from cells exposed to Triton-X100 and water. All wells were performed three times technically and repeated with additional donors. [Figure 15-2]This figure shows 1H7 CAR-T cells with intermediate and short spacers exhibiting antigen-specific enhanced cytotoxicity against multiple AML cell lines. Following IL-7 and IL-15 cytokine enhancement as shown in Figure 12, target cells were labeled with chromium 51 (Cr51) for 2 hours and then exposed to 1H7 CAR-T cells with short, intermediate (int), or long spacers for 4 hours. The supernatant was then collected and analyzed for Cr51 using a scintillation counter (TopCount, Perkin Elmer, Waltham, MA). Percent cytotoxicity was calculated as (sample lysis - background) / (maximum lysis - background lysis) × 100, where background lysis is the spontaneous release of Cr51 over 4 hours and maximum lysis is the release of Cr51 from cells exposed to Triton-X100 and water. All wells were performed three times technically and repeated with additional donors. [Figure 16] This figure shows antigen-specific enhanced proliferation of 1H7 CAR-T cells with int and short spacer lengths against multiple AML cell lines. As shown in Figure 12, 1H7 CAR-T cells with altered spacer lengths, following increased IL-7 and IL-15 cytokine levels, were labeled with carboxyfluorescein succinimidyl ester (CFSE) and co-cultured in medium alone or with designated target cells. CFSE dilutions were then measured by MFC after 4 days. The experiment was repeated with additional healthy donors to confirm the results. [Figure 17]This figure shows the acquisition of equivalent immune checkpoint markers in 1H7 CAR-T cells with short, intermediate, and long spacers following prolonged antigen exposure. As shown in Figure 12, 1H7 CAR-T cells with alternating spacer lengths were labeled with CFSE and co-cultured for 4 days in medium alone or with designated target cells, following an increase in IL-7 and IL-15 cytokines. Cells were stained with antibodies fluorescently conjugated to PD-1, LAG-3, and TIM-3, and the relative percentage of cells expressing all three (triple Pos), two (double Pos), one (single Pos), or none (triple Neg) immune checkpoints was assessed by MFC. Positive fluorescence for expressed proteins was relative to fluorescence minus one (FMO). Experiments were repeated with additional healthy donors to confirm the results. [Figure 18] This figure shows that 1H7 CAR-T cells with short and intermediate spacers exhibited the highest percentage of effector cytokine-positive cells in response to the antigen. Following the increase in IL-7 and IL-15 cytokines, 1H7 CAR-T cells with altered spacer lengths were co-cultured overnight with designated target cells, as shown in Figure 12. Protein secretion was then blocked for 4 hours using monensin, and the cells were then stained intracellularly with fluorescently conjugated antibodies for tumor necrosis factor α, interleukin-2, interferon-γ, and granzyme B. The relative percentages of all four effector molecules (quadruple Pos), three (triple Pos), two (double Pos), one (single Pos), or none (triple Neg) were assessed by MFC. Positive fluorescence for expressed proteins was relative to FMO. The experiment was repeated with additional healthy donors to confirm the results. [Figure 19-1]This figure shows CD4+1H7 CAR-T cells with short and intermediate spacers exhibiting enhanced anabolic activity of effector cytokines in response to antigens. Following the increase in IL-7 and IL-15 cytokines, CD4+1H7 CAR-T cells with altered spacer lengths were co-cultured overnight with designated target cells, as shown in Figure 12. The levels of secreted cytokines in the supernatant were then measured using LegendPlex (Biolegend, San Diego, CA) as per the manufacturer's instructions. [Figure 19-2] This figure shows CD4+1H7 CAR-T cells with short and intermediate spacers exhibiting enhanced anabolic activity of effector cytokines in response to antigens. Following the increase in IL-7 and IL-15 cytokines, CD4+1H7 CAR-T cells with altered spacer lengths were co-cultured overnight with designated target cells, as shown in Figure 12. The levels of secreted cytokines in the supernatant were then measured using LegendPlex (Biolegend, San Diego, CA) as per the manufacturer's instructions. [Figure 19-3] This figure shows CD4+1H7 CAR-T cells with short and intermediate spacers exhibiting enhanced anabolic activity of effector cytokines in response to antigens. Following the increase in IL-7 and IL-15 cytokines, CD4+1H7 CAR-T cells with altered spacer lengths were co-cultured overnight with designated target cells, as shown in Figure 12. The levels of secreted cytokines in the supernatant were then measured using LegendPlex (Biolegend, San Diego, CA) as per the manufacturer's instructions. [Figure 20-1] This figure shows CD8+1H7 CAR-T cells with short and intermediate spacers exhibiting enhanced anabolic activity of effector cytokines in response to antigens. As shown in Figure 12, CD8+1H7 CAR-T cells with altered spacer lengths were co-cultured overnight with designated target cells, following an increase in IL-7 and IL-15 cytokines. The levels of secreted cytokines in the supernatant were then measured using LegendPlex (Biolegend, San Diego, CA) as per the manufacturer's instructions. [Figure 20-2] This figure shows CD8+1H7 CAR-T cells with short and intermediate spacers exhibiting enhanced anabolic activity of effector cytokines in response to antigens. As shown in Figure 12, CD8+1H7 CAR-T cells with altered spacer lengths were co-cultured overnight with designated target cells, following an increase in IL-7 and IL-15 cytokines. The levels of secreted cytokines in the supernatant were then measured using LegendPlex (Biolegend, San Diego, CA) as per the manufacturer's instructions. [Figure 20-3] This figure shows CD8+1H7 CAR-T cells with short and intermediate spacers exhibiting enhanced anabolic activity of effector cytokines in response to antigens. As shown in Figure 12, CD8+1H7 CAR-T cells with altered spacer lengths were co-cultured overnight with designated target cells, following an increase in IL-7 and IL-15 cytokines. The levels of secreted cytokines in the supernatant were then measured using LegendPlex (Biolegend, San Diego, CA) as per the manufacturer's instructions. [Figure 21A]This figure shows enhanced cytotoxicity of 1H7 CAR-T cells with a short spacer compared to V-set oriented CAR-T cells using multiple donor samples. Following increased IL-7 and IL-15 cytokines as shown in Figure 12, ML1 or K562 target cells were labeled with Cr51 for 2 hours and then exposed to C2-(1H7) or V-set (My96 or RC1 CD33 binding segment) oriented CAR-T cells with a short spacer for 4 hours. The amino acid and nucleic acid sequences for My96 can be found in U.S. Patent No. 9,777,061, and RC1 CD33 scFv is provided as Sequence ID No. 366, described in U.S. Patent Application Publication No. 2016 / 0317657 A1. The supernatant was then collected and analyzed for Cr51 by a scintillation counter (TopCount, Perkin Elmer, Waltham, MA). Percent cytotoxicity was calculated as (sample lysis - background) / (maximum lysis - background lysis) × 100, where background lysis was the spontaneous release of Cr51 over 4 hours, and maximum lysis was the release of Cr51 from cells exposed to Triton-X100 and water. All wells were performed in three technical ways. **** p < 0.0001, ns Not significant by multiple t-tests using the two-step linear step-up procedure of Benjamini, Krieger and Yekutieli, Q = 1%. [Figure 21B]This figure shows enhanced cytotoxicity of 1H7 CAR-T cells with an intermediate spacer compared to V-set oriented CAR-T cells using multiple donor samples. Following increased IL-7 and IL-15 cytokine activity as shown in Figure 12, ML1 or K562 target cells were labeled with Cr51 for 2 hours and then exposed to C2-(1H7) or V-set (My96 or RC1 CD33 binding segment) oriented CAR-T cells with an int spacer for 4 hours. The amino acid and nucleic acid sequences for My96 can be found in U.S. Patent No. 9,777,061, and RC1 CD33 scFv is provided as Sequence ID No. 366, described in U.S. Patent Application Publication No. 2016 / 0317657 A1. The supernatant was then collected and analyzed for Cr51 by a scintillation counter (TopCount, Perkin Elmer, Waltham, MA). Percent cytotoxicity was calculated as (sample lysis - background) / (maximum lysis - background lysis) × 100, where background lysis was the spontaneous release of Cr51 over 4 hours, and maximum lysis was the release of Cr51 from cells exposed to Triton-X100 and water. All wells were performed in three technical ways. **** p < 0.0001, ns Not significant by multiple t-tests using the two-step linear step-up procedure of Benjamini, Krieger and Yekutieli, Q = 1%. [Figure 22] This figure shows enhanced expression of a viability-promoting tonic and antigen-induced AP-1 signaling in 1H7 CAR-T cells with an intermediate spacer. Jarcutt (J76) reporter cell lines expressing green fluorescent protein (GFP), cyan fluorescent protein (CFP), and mCherry from the nuclear factor (NFAT), nuclear factor κB (NFκB), and activator protein 1 (AP-1) promoters, respectively, were transduced with lentiviruses harboring 1H7 short, intermediate, or long CARs. The CAR-J76 cells were then co-cultured with target cells for 24 hours, and the geometric mean fluorescence intensity (geoMFI) of GFP, CFP, and mCherry was measured. [Figure 23]This figure shows the experimental setup for an in vivo study of CAR-T cells in immunodeficient mice. GFP-expressing, firefly luciferase (FFluc)-expressing human AML cell lines were intravenously (IV) injected into immunodeficient NOD.scid.IL2rg- / -(NSG) mice. Established disease developed over two weeks. In all cases where mice received CAR-T cells, they received IV injections of CD4+ and CD8+ CAR-T cells in a 1:1 ratio. If unrelated CAR-T cells were unavailable, phosphate-buffered saline (PBS) was used as a control. Mice were collected weekly to assess circulating tumors and CAR-T cells, and bioluminescence imaging (BLI) was performed weekly to assess disease burden following intraperitoneal injection of luciferin. Mice were then monitored for survival. [Figure 24A] Short and intermediate 1H7 CAR-T cells antigenically enhance survival in a xenograft model derived from the HL-60 cell line. As shown in Figure 23, mice were treated with 2 × 10⁶ HL-60 AML cells and 2 × 10⁶ 1H7 short or intermediate CAR-T cells or FMC63 CAR-T cells directed to an antigen (CD19) not expressed in HL-60 cells. Tumor bioluminescence imaging was evaluated weekly. Lines represent individual mice, n=5 per group, *p<0.05, **p<0.01 by log-rank test. [Figure 24B] Short and intermediate 1H7 CAR-T cells antigen-specifically enhance survival in a xenograft model derived from the HL-60 cell line. As shown in Figure 23, mice were treated with 2 × 10⁶ HL-60 AML cells and 2 × 10⁶ 1H7 short or intermediate CAR-T cells or FMC63 CAR-T cells directed to an antigen (CD19) not expressed in HL-60 cells. Mice were monitored for survival. Lines represent individual mice, n=5 per group, log-rank test results: *p<0.05, **p<0.01. [Figure 25]This figure shows the enhanced in vivo growth of 1H7 intermediate CAR-T cells compared to short spacer CAR-T cells in an HL-60 cell line-derived xenograft model. As shown in Figure 23, mice were treated with 2 × 10⁶ HL-60 AML cells and 2 × 10⁶ 1H7 short or intermediate CAR-T cells. Circulating CAR-T cell counts were assessed weekly by MFC. The dots represent the absolute CAR-T cell count in a single mouse, and the mean absolute circulating CAR-T cell count is represented by a single line. [Figure 26A] This figure shows that 1H7 intermediate CAR-T cells dose-dependently enhance survival in a xenograft model derived from the HL-60 cell line. As shown in Figure 23, mice were treated with 2 × 10⁶ HL-60 AML cells and 2 × 10⁶ or 1 × 10⁷ 1H7 intermediate CAR-T cells. Tumor bioluminescence imaging was evaluated weekly. Lines represent individual mice, n=5 per group, *p<0.05, **p<0.01 by log-rank test. [Figure 26B] This figure shows that 1H7 intermediate CAR-T cells dose-dependently enhance survival in a xenograft model derived from the HL-60 cell line. As shown in Figure 23, mice were treated with 2 × 10⁶ HL-60 AML cells and 2 × 10⁶ or 1 × 10⁷ 1H7 intermediate CAR-T cells. Mice were monitored for survival. Lines represent individual mice, n=5 per group, *p<0.05, **p<0.01 by log-rank test. [Figure 27A] This figure shows that 1H7 intermediate CAR-T cells enhance survival in a KG1α cell line-derived xenograft model. As shown in Figure 23, mice were treated with 2 × 10⁶ KG1α AML cells and 2 × 10⁶ 1H7 intermediate CAR-T cells or PBS. Tumor bioluminescence imaging was evaluated weekly. Lines represent individual mice, n=5 per group, **p<0.01 by log-rank test. [Figure 27B]This figure shows that 1H7 intermediate CAR-T cells enhance survival in a KG1α cell line-derived xenograft model. As shown in Figure 23, mice were treated with 2 × 10⁶ KG1α AML cells and 2 × 10⁶ 1H7 intermediate CAR-T cells or PBS. Mice were monitored for survival. Lines represent individual mice, n=5 per group, **p<0.01 by log-rank test. [Figure 28A] This figure shows antigen-negative relapse observed in a xenograft model derived from KG1α cell lines treated with 1H7 intermediate CAR-T cells. As shown in Figure 23, mice were treated with 2 × 10⁶ KG1α AML cells and 2 × 10⁶ 1H7 intermediate CAR-T cells or PBS. Peripheral blood tests were performed weekly to assess CD33 expression on circulating tumor cells by MFCs. Lines represent the mean CD33-positive and CD33-negative cells per mouse, with n=3 in the PBS group and n=5 in the CAR-T cell group. [Figure 28B] This figure shows antigen-negative relapse observed in a xenograft model derived from KG1α cell lines treated with 1H7 intermediate CAR-T cells. As shown in Figure 23, mice were treated with 2 × 10⁶ KG1α AML cells and 2 × 10⁶ 1H7 intermediate CAR-T cells or PBS. At the end of the experiment, tissue was harvested and CD33 tumor expression was evaluated by MFC. Lines represent the mean CD33-positive and CD33-negative cells per mouse, n=3 in the PBS group and n=5 in the CAR-T cell group. [Figure 29A] This figure shows that cytokine enhancement of 1H7 CAR-T cells using IL-21 enhances survival in a xenograft model derived from the MOLM-14 cell line. As shown in Figure 23, mice were treated with 5 × 10⁵ MOLM-14 AML cells and 5 × 10⁵ 1H7 intermediate CAR-T cells enhanced with IL-7 and IL-15 (1H7.int CAR-T) or IL-7, IL-15 and IL-21 (1H7.int CAR-T + IL-21). Tumor bioluminescence imaging was evaluated weekly. Lines represent individual mice, n=5 per group, **p<0.01 by log-rank test. [Figure 29B]This figure shows that cytokine enhancement of 1H7 CAR-T cells using IL-21 enhances survival in a xenograft model derived from the MOLM-14 cell line. As shown in Figure 23, mice were treated with 5 × 10⁵ MOLM-14 AML cells and 5 × 10⁵ 1H7 intermediate CAR-T cells enhanced with IL-7 and IL-15 (1H7.int CAR-T) or IL-7, IL-15 and IL-21 (1H7.int CAR-T + IL-21). Mice were monitored for survival. Lines represent individual mice, n=5 per group, **p<0.01 by log-rank test. [Figure 30A] This figure shows CD33-directed 9G2 and 6H9 short CAR-T cells exhibiting equal cytotoxicity. Two scFvs directed to the C2 set domain of CD33 were cloned into the short CAR skeleton. Next, T cells modified to express either the 6H9 short or 9G2 short CAR were enlarged with IL-7 and IL-15. These cells were then evaluated for cytotoxicity in response to target cells previously described in Figure 15. [Figure 30B] This figure shows CD33-directed 9G2 and 6H9 short CAR-T cells with equal proliferation. Two scFvs directed to the C2 set domain of CD33 were cloned into the short CAR skeleton. Next, T cells modified to express the 6H9 short or 9G2 short CAR were enlarged with IL-7 and IL-15. These cells were then evaluated for proliferation in response to target cells previously described in Figure 16. [Figure 30C] This figure shows CD33-directed 9G2 and 6H9 short CAR-T cells with equal effector molecule expression. Two scFvs directed to the C2 set domain of CD33 were cloned into the short CAR skeleton. Next, T cells modified to express either the 6H9 short or 9G2 short CAR were enlarged with IL-7 and IL-15. These cells were then evaluated for effector cytokine production (TNFα, IL-2, IFNγ, and GzB) in response to target cells previously described in Figure 18. [Figure 31]This figure shows antigen-specific lysis in vitro of 1H7 CD33-directed CAR-T cells with an intermediate spacer against multiple AML cell lines. Cr51-labeled KG1a and ML-1 cells expressing endogenous CD33 (Par) or lacking CD33 due to CRISPR-Cas9 gene deletion (KO) were exposed for 4 hours to CD33-directed CD8+ CAR-T cells augmented with IL-2 (50 ng / mL), IL-7 & IL-15 (10 ng / mL each), or IL-7, IL-15 & IL-21 (10 ng / mL each) in various effector:target ratios. The supernatant was harvested and analyzed for Cr51 concentration by scintillation. [Figure 32A] This figure shows improved in vitro antigen-specific cytotoxicity of CAR-T cells targeting the 9G2 and 1H7 membrane proximal domains (C2 set) compared to CAR-T cells targeting the membrane distal domains (V set). V set-targeted CD33-oriented (My96, 32A) or C2 set-targeted CD33-oriented (1H7, 32B, and 9G2, 32C) CAR-T cells were augmented with IL-7 and IL-15, as shown in Figure 23. Target cells were labeled with Cr51 for 2 hours and then exposed to CAR-T cells with short spacers for 4 hours. The supernatant was then collected and analyzed for Cr51 using a scintillation counter (TopCount, Perkin Elmer, Waltham, MA). Percent cytotoxicity was calculated as (sample lysis - background) / (maximum lysis - background lysis) × 100, where background lysis is the spontaneous release of Cr51 over 4 hours, and maximum lysis is the release of Cr51 from cells exposed to Triton-X100 and water. All wells were run in three technical ways. Specific cytotoxicity (31D) against AML targets expressing high (ML-1) or low (K562) levels of CD33 was compared across all three CAR-T cell constructs. ****p<0.0001, ***p<0.001 for 9G2 vs. My96; and ##p<0.01, ns. Two-way ANOVA with post-hoc Tukey comparisons showed no significant difference between 1H7 and My96. [Figure 32B]This figure shows improved in vitro antigen-specific cytotoxicity of CAR-T cells targeting the 9G2 and 1H7 membrane proximal domains (C2 set) compared to CAR-T cells targeting the membrane distal domains (V set). V set-targeted CD33-oriented (My96, 32A) or C2 set-targeted CD33-oriented (1H7, 32B, and 9G2, 32C) CAR-T cells were augmented with IL-7 and IL-15, as shown in Figure 23. Target cells were labeled with Cr51 for 2 hours and then exposed to CAR-T cells with short spacers for 4 hours. The supernatant was then collected and analyzed for Cr51 using a scintillation counter (TopCount, Perkin Elmer, Waltham, MA). Percent cytotoxicity was calculated as (sample lysis - background) / (maximum lysis - background lysis) × 100, where background lysis is the spontaneous release of Cr51 over 4 hours, and maximum lysis is the release of Cr51 from cells exposed to Triton-X100 and water. All wells were run in three technical ways. Specific cytotoxicity (31D) against AML targets expressing high (ML-1) or low (K562) levels of CD33 was compared across all three CAR-T cell constructs. ****p<0.0001, ***p<0.001 for 9G2 vs. My96; and ##p<0.01, ns. Two-way ANOVA with post-hoc Tukey comparisons showed no significant difference between 1H7 and My96. [Figure 32C]This figure shows improved in vitro antigen-specific cytotoxicity of CAR-T cells targeting the 9G2 and 1H7 membrane proximal domains (C2 set) compared to CAR-T cells targeting the membrane distal domains (V set). V set-targeted CD33-oriented (My96, 32A) or C2 set-targeted CD33-oriented (1H7, 32B, and 9G2, 32C) CAR-T cells were augmented with IL-7 and IL-15, as shown in Figure 23. Target cells were labeled with Cr51 for 2 hours and then exposed to CAR-T cells with short spacers for 4 hours. The supernatant was then collected and analyzed for Cr51 using a scintillation counter (TopCount, Perkin Elmer, Waltham, MA). Percent cytotoxicity was calculated as (sample lysis - background) / (maximum lysis - background lysis) × 100, where background lysis is the spontaneous release of Cr51 over 4 hours, and maximum lysis is the release of Cr51 from cells exposed to Triton-X100 and water. All wells were run in three technical ways. Specific cytotoxicity (31D) against AML targets expressing high (ML-1) or low (K562) levels of CD33 was compared across all three CAR-T cell constructs. ****p<0.0001, ***p<0.001 for 9G2 vs. My96; and ##p<0.01, ns. Two-way ANOVA with post-hoc Tukey comparisons showed no significant difference between 1H7 and My96. [Figure 32D]This figure shows improved in vitro antigen-specific cytotoxicity of CAR-T cells targeting the 9G2 and 1H7 membrane proximal domains (C2 set) compared to CAR-T cells targeting the membrane distal domains (V set). V set-targeted CD33-oriented (My96, 32A) or C2 set-targeted CD33-oriented (1H7, 32B, and 9G2, 32C) CAR-T cells were augmented with IL-7 and IL-15, as shown in Figure 23. Target cells were labeled with Cr51 for 2 hours and then exposed to CAR-T cells with short spacers for 4 hours. The supernatant was then collected and analyzed for Cr51 using a scintillation counter (TopCount, Perkin Elmer, Waltham, MA). Percent cytotoxicity was calculated as (sample lysis - background) / (maximum lysis - background lysis) × 100, where background lysis is the spontaneous release of Cr51 over 4 hours, and maximum lysis is the release of Cr51 from cells exposed to Triton-X100 and water. All wells were run in three technical ways. Specific cytotoxicity (31D) against AML targets expressing high (ML-1) or low (K562) levels of CD33 was compared across all three CAR-T cell constructs. ****p<0.0001, ***p<0.001 for 9G2 vs. My96; and ##p<0.01, ns. Two-way ANOVA with post-hoc Tukey comparisons showed no significant difference between 1H7 and My96. [Figure 33A] This figure shows improved in vitro proliferation of 9G2 and 1H7 membrane proximal domain (C2 set) targeted CAR-T cells compared to membrane distal domain (V set) targeted CAR-T cells. V set targeted CD33-oriented (My96) or C2 set targeted CD33-oriented (1H7 and 9G2) CAR-T cells were enlarged with IL-7 and IL-15 as shown in Figure 12. Next, the CAR-T cells were labeled with CFSE and cultured in medium alone or co-cultured with indicated target cells. Then, CFSE dilution was measured by MFC after 4 days. [Figure 33B]This figure shows improved in vitro proliferation of 9G2 and 1H7 membrane proximal domain (C2 set) targeted CAR-T cells compared to membrane distal domain (V set) targeted CAR-T cells. V set targeted CD33-oriented (My96) or C2 set targeted CD33-oriented (1H7 and 9G2) CAR-T cells were enlarged with IL-7 and IL-15 as shown in Figure 12. Next, the CAR-T cells were labeled with CFSE and cultured in medium alone or co-cultured with indicated target cells. Then, mitotic vs. non-mitotic cells were quantified by the first peak under medium alone conditions. [Figure 33C] This figure shows improved in vitro proliferation of 9G2 and 1H7 membrane proximal domain (C2 set) targeted CAR-T cells compared to membrane distal (V set) targeted CAR-T cells. V set targeted CD33-directed (My96) or C2 set targeted CD33-directed (1H7 and 9G2) CAR-T cells were enlarged with IL-7 and IL-15 as shown in Figure 12. Next, the CAR-T cells were labeled with CFSE and cultured in medium alone or co-cultured with indicated target cells. Specific mitosis against AML targets expressing high (ML1) or low (K562) levels of CD33 was compared across all three CAR-T cell constructs. [Figure 34A]This figure shows that CAR-T cells targeting the 9G2 and 1H7 membrane proximal domains (C2 set) exhibited equal immune checkpoint expression in a quiescent state compared to CAR-T cells targeting the membrane distal (V set). As shown in Figure 12, following an increase in IL-7 and IL-15 cytokines, CAR-T cell targeting membrane distal V set domains (My96) or membrane proximal C2 set domains (1H7 and 9G2) were co-cultured with target cells or culture medium. The cells were then stained with antibodies fluorescently conjugated to PD-1, LAG-3, and TIM-3, and the relative proportion of cells expressing all three immune checkpoints (triple Pos), two (double Pos), one (single Pos), or none (triple Neg) was assessed by MFC (34A). Positive fluorescence for expressed proteins was relative to FMO. Specific immune checkpoint expression in CAR-T cells without antigen stimulation (34B). [Figure 34B] This figure shows that CAR-T cells targeting the 9G2 and 1H7 membrane proximal domains (C2 set) exhibited equal immune checkpoint expression in a quiescent state compared to CAR-T cells targeting the membrane distal (V set). As shown in Figure 12, following an increase in IL-7 and IL-15 cytokines, CAR-T cell targeting membrane distal V set domains (My96) or membrane proximal C2 set domains (1H7 and 9G2) were co-cultured with target cells or culture medium. The cells were then stained with antibodies fluorescently conjugated to PD-1, LAG-3, and TIM-3, and the relative proportion of cells expressing all three immune checkpoints (triple Pos), two (double Pos), one (single Pos), or none (triple Neg) was assessed by MFC (34A). Positive fluorescence for expressed proteins was relative to FMO. Specific immune checkpoint expression in CAR-T cells without antigen stimulation (34B). [Figure 35A]This figure shows improved in vitro multifunctional cytokine production in CAR-T cells targeting the 9G2 and 1H7 membrane proximal domains (C2 set) compared to CAR-T cells targeting the membrane distal (V set). Following increased IL-7 and IL-15 cytokine production, as shown in Figure 12, CAR-T cell targeting the membrane distal V set domain (My96) or the membrane proximal C2 set domain (1H7 and 9G2) was co-cultured overnight with the indicated target cells. Protein secretion was then blocked for 4 hours using monensin, and the cells were then intracellularly stained with fluorescently conjugated antibodies for tumor necrosis factor α, interleukin-2, interferon-γ, and granzyme B. The relative proportions of all four effector molecules (quadruple Pos), three (triple Pos), two (double Pos), one (single Pos), or none (triple Neg) were assessed by MFC. The positive fluorescence of the expressed protein was relative to FMO. [Figure 35B] This figure shows improved in vitro multifunctional cytokine production in 9G2 and 1H7 membrane proximal domain (C2 set) targeted CAR-T cells compared to membrane distal (V set) targeted CAR-T cells. Following increased IL-7 and IL-15 cytokine levels, as shown in Figure 12, CAR-T cell-targeting membrane distal V set domain (My96) or membrane proximal C2 set domain (1H7 and 9G2) were co-cultured overnight with designated target cells. Specific intracellular cytokine production against AML targets expressing high (ML1) or low (K562) levels of CD33 was compared across all three CAR-T cell constructs. Positive fluorescence for expressed proteins was relative to FMO. [Figure 36-1]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-2]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-3]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-4]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-5]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-6]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-7]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-8]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-9]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-10]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-11]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-12]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-13]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-14]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-15]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-16]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-17]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-18]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-19]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-20]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-21]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-22]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-23]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-24]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-25]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-26]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-27]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-28]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-29]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-30]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-31]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-32]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-33]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-34]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-35]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-36]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A (SEQ ID NO: 28); EF1 promoter-B (SEQ ID NO: 29); Psi (SEQ ID NO: 30); RRE (SEQ ID NO: 31); Flap (SEQ ID NO: 32); GM-CSFR encoding sequence (SEQ ID NO: 33); WPRE (SEQ ID NO: 34); delU3 (SEQ ID NO: 35); R (SEQ ID NO: 36); U5 (SEQ ID NO: 37); AmpR (SEQ ID NO: 38); CoE1 origin (SEQ ID NO: 39); SV40 (SEQ ID NO: 40); CMV (SEQ ID NO: 41); Glycosylation site; 1H7-intDS-41bb-3z-T-CD19t top chain (SEQ ID NO: 42); 1H7-long-41bb-3z-T-CD19t top chain (SEQ ID NO: 43);1H7-sh-41bb-3z-T-CD19t top strand (SEQ ID NO: 44); 6H9-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 45); 9G2-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 46); 5D12-intDS-41bb-3z-T-CD19t top strand (SEQ ID NO: 47); CD33:CD22 4D protein (SEQ ID NO: 105); CD33:CD22 4D nucleotide (SEQ ID NO: 106); CD33:CD22 2D protein (SEQ ID NO: 107); CD33:CD22 2D nucleotide (SEQ ID NO: 108); CD33 V-set construct (exon 3 and 4 deletion) protein (SEQ ID NO: 109); CD33 V-set construct (exon 3 and 4 deletion) nucleotide (SEQ ID NO: 110); CD33 signal peptide (SEQ ID NO: 111); CD33 signal peptide coding sequence (SEQ ID NO: 112); 6-histidine tag coding sequence (Sequence No. 113); 3× glycine linker; 3× glycine linker coding sequence; CD33 ECD (Sequence No. 114); CD33 ECD coding sequence (Sequence No. 115); CD33 ECD lacking amino acids 140-232 (Sequence No. 116); CD33 ECD coding sequence lacking amino acids 140-232 (Sequence No. 117); CD33 transmembrane domain (Sequence No. 118); CD33 transmembrane domain coding sequence (Sequence No. 119); CD33 intracellular domain (Sequence No. 120); CD33 intracellular domain coding sequence (Sequence No. 121); CD22 Part of the ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 122); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 3, Ig-like C2 type 4, Ig-like C2 type 5, and Ig-like C2 type 6 (sequence number 123); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 124); Part of the CD22 ECD containing CD22 domains defined as Ig-like C2 type 5 and Ig-like C2 type 6 (sequence number 125); 1H7 VLVH scFv code sequence (sequence number 126); 3A5 variant 1 VHVL scFv code sequence (sequence number 127);3A5 Variant 1 VLVH scFv code array (array number 128); 3A5 Variant 2 VHVL scFv code array (array number 129); 3A5 Variant 2 VLVH scFv code array (array number 130); 9G2 VLVH scFv code array (array number 131); 7D5 Variant 1 VHVL scFv code array (array number 132); 7D5 Variant 2 VHVL scFv code sequence (sequence number 133); signal peptide code sequence (sequence number 134); G4S×3 linker code sequence (sequence number 135); 1H7 variable light chain code sequence (sequence number 136); 1H7 variable heavy chain code sequence (sequence number 137); 3A5 variant 1 and variant 2 variable light chain code sequence (sequence number 138); 3A5 variant 1 variable heavy chain code sequence (sequence number 139); 3A5 variant 2 variable heavy chain code sequence (sequence number 140); 9G2 variable light chain code sequence (sequence number 141); 9G2 variable heavy chain code sequence (sequence number 142); 7D5 variant 1 and variant 2 variable light chain code sequence (sequence number 143); 7D5 variant 1 variable heavy chain code sequence (sequence number 144); 7D5 variant 2 variable heavy chain code sequence (sequence number 144); 145); 5D12-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 325); 3A5v1-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 326); 3A5v2-HvLv-intDS-41bb-3z-T-CD19t top chain (sequence number 327); 3A5v1-LvHv-intDS-41 bb-3z-T-CD19t top chain (sequence number 328); 3A5v2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 329); 1H7-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 330); 9G2-LvHv-intDS-41bb-3z-T-CD19t top chain (sequence number 331); 1H7 scFv VH-VL orientation (sequence code 332); 1H7 scFv VL-VH orientation (sequence code 333); 9G2 scFv VH-VL orientation (sequence code 334); 9G2 scFv VL-VH orientation (sequence code 335); 5D12 scFv VH-VL orientation (sequence code 336); 5D12 scFv VL-VH orientation (sequence code 337); 3A5 variant 1 scFv VH-VL orientation (sequence code 338);3A5 variant 1 scFv VL-VH orientation (SEQ ID NO: 339); 3A5 variant 2 scFv VH-VL orientation (SEQ ID NO: 340); 3A5 variant 2 scFv VL-VH orientation (SEQ ID NO: 341); Human CD33 full-length DNA coding sequence (SEQ ID NO: 342); Human CD33 full-length protein (SEQ ID NO: 343); Light chain signal peptide of 9G2 and / or 6H9 (SEQ ID NO: 344); Light chain signal peptide of 3A5v1, 3A5v2, and / or 2D5 (SEQ ID NO: 345); Light chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 346); Light chain signal peptide of 11D5 (SEQ ID NO: 347); Heavy chain signal peptide of 6H9 (SEQ ID NO: 347) 348); Heavy chain signal peptide of 3A5v1 and / or 3A5v2 (SEQ ID NO: 349); Heavy chain signal peptide of 7D5v1 and / or 7D5v2 (SEQ ID NO: 350); Heavy chain signal peptide of 2D5 (SEQ ID NO: 351); Heavy chain signal peptide of 11D5 (SEQ ID NO: 352); Heavy chain signal peptide of 13E11 (SEQ ID NO: 353); My96 coding sequence (SEQ ID NO: 354); My96_int_41BB_3z_TCD19 coding sequence (SEQ ID NO: 355); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 377); V-set oriented CD33 / CD3 BsAb(RC1) (SEQ ID NO: 378); and V-set oriented scFv protein sequence (SEQ ID NO: 366) and coding sequence (SEQ ID NO: 370). [Figure 36-37]Sequences supporting this disclosure: CD33 / CD3 bispecific molecule (SEQ ID NO: 220); 1H7 scFv coding sequence (SEQ ID NO: 1); 6H9 scFv coding sequence, codon optimized (SEQ ID NO: 2); 9G2 scFv coding sequence, codon optimized (SEQ ID NO: 3); 2D5 scFv coding sequence (SEQ ID NO: 4); 5D12 scFv coding sequence (SEQ ID NO: 5); IgG4 hinge coding sequence-A (SEQ ID NO: 6); IgG4 hinge coding sequence-B (SEQ ID NO: 7); IgG4-int(DS) coding sequence (SEQ ID NO: 8); IgG4-long coding sequence (SEQ ID NO: 9); CD3ζ coding sequence (SEQ ID NO: 10); CD3ζ protein-A (SEQ ID NO: 11); CD3ζ protein-B (SEQ ID NO: 12); 4-1BB signal transduction coding sequence-A (SEQ ID NO: 13); 4-1BB signal transduction coding sequence-B (SEQ ID NO: 14); 4-1BB protein-A (SEQ ID NO: 15); 4-1BB protein-B (SEQ ID NO: 16); CD28™ code sequence-A (sequence number 17); CD28™ code sequence-B (sequence number 18); CD28™ code sequence-C (sequence number 19); CD28™ protein-A (sequence number 20); CD28™ protein-B (sequence number 21); tCD19 code sequence (sequence number 22); T2A code sequence (sequence number 23); Thoseaasigna virus 2A (T2A) peptide (sequence number 24); Teschovirus-1 2A(P2A) peptide (SEQ ID NO: 25); Equine rhinitis A virus (ERAV) 2A(E2A) peptide (SEQ ID NO: 26); Foot-and-mouth disease virus 2A(F2A) peptide (SEQ ID NO: 27); EF1 promoter-A ...

Claims

1. An extracellular component comprising a binding domain having a complementarity-determining region (CDR) set for antibody 9G2, 6H9, 3a5v1, 3A5v2, 7D5v1, or 7D5v2, According to North, 9G2 includes CDRL1 having the sequence of SEQ ID NO: 62, CDRL2 having the sequence of SEQ ID NO: 57, CDRL3 having the sequence of SEQ ID NO: 58, CDRH1 having the sequence of SEQ ID NO: 63, CDRH2 having the sequence of SEQ ID NO: 64, and CDRH3 having the sequence of SEQ ID NO: 65; According to IMGT, 9G2 includes CDRL1 having the sequence of SEQ ID NO: 227, CDRL2 having the sequence YTS, CDRL3 having the sequence of SEQ ID NO: 58, CDRH1 having the sequence of SEQ ID NO: 228, CDRH2 having the sequence of SEQ ID NO: 229, and CDRH3 having the sequence of SEQ ID NO: 65; According to Kabat, 9G2 includes CDRL1 having the sequence of SEQ ID NO: 62, CDRL2 having the sequence of SEQ ID NO: 159, CDRL3 having the sequence of SEQ ID NO: 58, CDRH1 having the sequence of SEQ ID NO: 273, CDRH2 having the sequence of SEQ ID NO: 274, and CDRH3 having the sequence of SEQ ID NO: 275; According to Chothia, 9G2 includes CDRL1 having the sequence of SEQ ID NO: 62, CDRL2 having the sequence of SEQ ID NO: 159, CDRL3 having the sequence of SEQ ID NO: 58, CDRH1 having the sequence of SEQ ID NO: 307, CDRH2 having the sequence of SEQ ID NO: 308, and CDRH3 having the sequence of SEQ ID NO: 275; According to North, 6H9 includes CDRL1 having the sequence of sequence number 56, CDRL2 having the sequence of sequence number 57, CDRL3 having the sequence of sequence number 58, CDRH1 having the sequence of sequence number 59, CDRH2 having the sequence of sequence number 60, and CDRH3 having the sequence of sequence number 61; According to IMGT, 6H9 includes CDRL1 having the sequence of SEQ ID NO: 223, CDRL2 having the sequence YTS, CDRL3 having the sequence of SEQ ID NO: 58, CDRH1 having the sequence of SEQ ID NO: 225, CDRH2 having the sequence of SEQ ID NO: 226, and CDRH3 having the sequence of SEQ ID NO: 61; According to Kabat, 6H9 includes CDRL1 having the sequence of SEQ ID NO: 56, CDRL2 having the sequence of SEQ ID NO: 159, CDRL3 having the sequence of SEQ ID NO: 58, CDRH1 having the sequence of SEQ ID NO: 270, CDRH2 having the sequence of SEQ ID NO: 271, and CDRH3 having the sequence of SEQ ID NO: 272; According to Chothia, 6H9 includes CDRL1 having the sequence of SEQ ID NO: 56, CDRL2 having the sequence of SEQ ID NO: 159, CDRL3 having the sequence of SEQ ID NO: 58, CDRH1 having the sequence of SEQ ID NO: 305, CDRH2 having the sequence of SEQ ID NO: 306, and CDRH3 having the sequence of SEQ ID NO: 272; According to North, 3A5v1 includes CDRL1 having the sequence of sequence number 184, CDRL2 having the sequence of sequence number 185, CDRL3 having the sequence of sequence number 68, CDRH1 having the sequence of sequence number 186, CDRH2 having the sequence of sequence number 187, and CDRH3 having the sequence of sequence number 188; According to IMGT, 3A5v1 includes CDRL1 having the sequence of sequence number 237, CDRL2 having the sequence LAS, CDRL3 having the sequence of sequence number 68, CDRH1 having the sequence of sequence number 239, CDRH2 having the sequence of sequence number 240, and CDRH3 having the sequence of sequence number 188; According to Kabat, 3A5v1 includes CDRL1 having the sequence of sequence number 184, CDRL2 having the sequence of sequence number 280, CDRL3 having the sequence of sequence number 68, CDRH1 having the sequence of sequence number 281, CDRH2 having the sequence of sequence number 282, and CDRH3 having the sequence of sequence number 283; According to Chothia, 3A5v1 includes CDRL1 having the sequence of sequence number 184, CDRL2 having the sequence of sequence number 280, CDRL3 having the sequence of sequence number 68, CDRH1 having the sequence of sequence number 309, CDRH2 having the sequence of sequence number 312, and CDRH3 having the sequence of sequence number 283; According to North, 3A5v2 includes CDRL1 having the sequence of sequence number 184, CDRL2 having the sequence of sequence number 185, CDRL3 having the sequence of sequence number 68, CDRH1 having the sequence of sequence number 186, CDRH2 having the sequence of sequence number 187, and CDRH3 having the sequence of sequence number 189; According to IMGT, 3A5v2 includes CDRL1 having the sequence of sequence number 237, CDRL2 having the sequence LAS, CDRL3 having the sequence of sequence number 68, CDRH1 having the sequence of sequence number 239, CDRH2 having the sequence of sequence number 240, and CDRH3 having the sequence of sequence number 189; According to Kabat, 3A5v2 includes CDRL1 having the sequence of sequence number 184, CDRL2 having the sequence of sequence number 280, CDRL3 having the sequence of sequence number 68, CDRH1 having the sequence of sequence number 281, CDRH2 having the sequence of sequence number 282, and CDRH3 having the sequence of sequence number 284; According to Chothia, 3A5v2 includes CDRL1 having the sequence of sequence number 184, CDRL2 having the sequence of sequence number 280, CDRL3 having the sequence of sequence number 68, CDRH1 having the sequence of sequence number 309, CDRH2 having the sequence of sequence number 312, and CDRH3 having the sequence of sequence number 284; According to North, 7D5v1 includes CDRL1 having sequence number 190, CDRL2 having sequence number 191, CDRL3 having sequence number 192, CDRH1 having sequence number 193, CDRH2 having sequence number 194, and CDRH3 having sequence number 195; According to IMGT, 7D5v1 includes CDRL1 having sequence number 241, CDRL2 having sequence YAS, CDRL3 having sequence number 192, CDRH1 having sequence number 243, CDRH2 having sequence number 244, and CDRH3 having sequence number 195; According to Kabat, 7D5v1 includes CDRL1 having the sequence of sequence number 190, CDRL2 having the sequence of sequence number 285, CDRL3 having the sequence of sequence number 192, CDRH1 having the sequence of sequence number 286, CDRH2 having the sequence of sequence number 287, and CDRH3 having the sequence of sequence number 288; According to Chothia, 7D5v1 includes CDRL1 having the sequence of sequence number 190, CDRL2 having the sequence of sequence number 285, CDRL3 having the sequence of sequence number 192, CDRH1 having the sequence of sequence number 313, CDRH2 having the sequence of sequence number 314, and CDRH3 having the sequence of sequence number 288; According to North, 7D5v2 includes CDRL1 having sequence number 190, CDRL2 having sequence number 191, CDRL3 having sequence number 192, CDRH1 having sequence number 193, CDRH2 having sequence number 194, and CDRH3 having sequence number 196; According to IMGT, 7D5v2 includes CDRL1 having sequence number 241, CDRL2 having sequence YAS, CDRL3 having sequence number 192, CDRH1 having sequence number 243, CDRH2 having sequence number 244, and CDRH3 having sequence number 196; According to Kabat, 7D5v2 includes CDRL1 having the sequence of SEQ ID NO: 190, CDRL2 having the sequence of SEQ ID NO: 285, CDRL3 having the sequence of SEQ ID NO: 192, CDRH1 having the sequence of SEQ ID NO: 286, CDRH2 having the sequence of SEQ ID NO: 293, and CDRH3 having the sequence of SEQ ID NO: 289; or According to Chothia, 7D5v2 is an extracellular component comprising CDRL1 having the sequence of SEQ ID NO: 190, CDRL2 having the sequence of SEQ ID NO: 285, CDRL3 having the sequence of SEQ ID NO: 192, CDRH1 having the sequence of SEQ ID NO: 313, CDRH2 having the sequence of SEQ ID NO: 314, and CDRH3 having the sequence of SEQ ID NO: 289; Intracellular components including effector domains; and Transmembrane domains that link extracellular components to intracellular components A chimeric antigen receptor (CAR) that contains and binds to CD33.

2. The binding domain includes a single-stranded variable fragment (scFv), The single-stranded variable fragment is Sequence ID 3, 9G2 VHVL scFv code sequence; Sequence ID 131, 9G2 VLVH scFv code sequence; Sequence ID 2, 6H9 VHVL scFv code sequence; VHVL scFv code sequence for 3A5 variant 1 of sequence number 127; Sequence ID 128, 3A5 variant 1, VLVH scFv code sequence; Sequence ID 129, 3A5 variant 2, VHVL scFv code sequence; Sequence ID 130, 3A5 variant 2, VLVH scFv code sequence; Sequence ID 132, 7D5 variant 1, VHVL scFv code sequence; or Sequence ID 133, 7D5 variant 2, VHVL scFv code sequence; A CAR according to claim 1, which is coded by [the specified method].

3. The CAR according to claim 1, wherein the binding domain has the sequence of SEQ ID NO: 334, SEQ ID NO: 335, SEQ ID NO: 338, SEQ ID NO: 339, SEQ ID NO: 340, or SEQ ID NO:

341.

4. The CAR according to claim 1, further comprising a spacer region in which an extracellular component is encoded by the sequence of SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO:

8.

5. The CAR according to claim 1, wherein the effector domain comprises all or part of the signaling domain of CD3ζ; all or part of the signaling domain of 4-1BB; all or part of the signaling domain of CD28; all or part of the signaling domains of CD3ζ and 4-1BB; all or part of the signaling domains of CD3ζ and CD28; or all or part of the signaling domains of CD3ζ, 4-1BB, and CD28.

6. The CAR according to claim 5, wherein the CD3ζ signaling domain comprises the sequence of SEQ ID NO: 11 or 12, and the 4-1BB signaling domain comprises the sequence of SEQ ID NO: 15 or 16.

7. The CAR according to claim 1, wherein the transmembrane domain comprises a CD28 transmembrane domain containing the sequence of SEQ ID NO: 20 or SEQ ID NO:

21.

8. A gene construct encoding CAR as described in claim 1.

9. The gene construct according to claim 8, wherein the gene construct comprises the sequence of SEQ ID NO: 46, SEQ ID NO: 331, SEQ ID NO: 45, SEQ ID NO: 326, SEQ ID NO: 327, SEQ ID NO: 328, or SEQ ID NO:

329.

10. Nanoparticles that encapsulate the gene construct according to claim 8.

11. A cell genetically modified to express the CAR described in any one of claims 1 to 7.

12. The cell according to claim 11, wherein the cell is a T cell, a B cell, a natural killer (NK) cell, an NK-T cell, a monocyte / macrophage, a hematopoietic stem cell (HSC), or a hematopoietic progenitor cell (HPC).

13. The cell according to claim 11, wherein the cell is a CD8+ T cell.

14. The cells according to claim 11, wherein the cells are incubated in a cell medium containing IL-2, IL-7, IL-15, and / or IL-21.

15. A population of cells according to any one of claims 11 to 14, formulated for administration to a target.

16. A pharmaceutical composition for use in a method for treating a subject having a CD33-related disorder, wherein the pharmaceutical composition comprises a therapeutically effective amount of nanoparticles according to claim 10 or a cell population according to claim 15, and the method comprises administering a therapeutically effective amount of nanoparticles according to claim 10 or a cell population according to claim 15 to a subject, thereby treating the subject having a CD33-related disorder.

17. The pharmaceutical composition according to claim 16, wherein the CD33-related disorder includes acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CML), mast cell leukemia, myelodysplastic syndrome (MDS), B-cell acute lymphoblastic leukemia (B-ALL), T-cell acute lymphoblastic leukemia (T-ALL), or megakaryocytic leukemia.

Images